Antimicrobial resistance is a silent pandemic. Evaluate India's regulatory response, including recent changes to drug-approval rules.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →In this answer
Antimicrobial resistance (AMR) happens when microbes stop responding to the drugs used against them. It kills quietly, through infections that can no longer be treated, and the Union Health Ministry calls it a major global public-health concern [1]. India's response is sound in design, but its enforcement is still catching up.
Strengths of the regulatory response
- Policy framework: The first NAP-AMR (2017–21) set out a One Health approach covering the human, animal and food sectors [2]. An updated second plan followed in 2025.
- Tighter approval (2026 draft): The NDCT Rules, 2019 are to be amended so that 'antimicrobials' count as 'New Drugs'. This would require central scrutiny before any manufacturing licence is granted [1].
- Bulk-drug traceability: A separate application and licence form for selling bulk drugs under the Drugs Rules, 1945 would keep the trade in active ingredients apart from formulation licensing [1].
- Closing a federal gap: The 59th Standing Committee Report (2012) exposed lapses in how CDSCO approves new drugs [3]. Bringing all antimicrobials under central approval narrows the gap between who approves a drug and who licenses its manufacture.
- Retail curbs: Schedule H1 restricts over-the-counter sale of specified antibiotics.
Weaknesses
- Capacity deficit: The 2013 Standing Committee found weak drug-control infrastructure at both State and central levels [4]. Moving files to the Centre without adding staff only moves the delay, and it may slow launches of cheap generics.
- Factory, not counter: Licensing reforms do not reach chemists, where antibiotics are still often sold without prescriptions.
- Legacy products: Past bans on irrational fixed-dose combinations (FDCs) were held up by litigation. The draft does not say how it will treat antimicrobials already on the market.
- Environmental blind spot: WHO notes that antibiotic pollution from manufacturing is largely unregulated [5]. The new licence tracks who sells bulk drugs, not what factories discharge.
- Still a draft: These are proposals, not notified law [1].
Verdict and way forward India's response is well designed but enforced unevenly along the chain from approval to licence, retail sale and the environment. Centralisation should come with more CDSCO staff and statutory deadlines, in line with the 2013 committee's call to fix weak infrastructure [4]. WHO's discharge targets could become licence conditions for bulk-antibiotic makers [5], and digital audits of prescriptions could close the retail gap. Enforcing One Health at every link would turn the quiet pandemic into a managed risk, in line with Article 47 and SDG 3.
Sources
- 1Ministry seeks tighter norms for antimicrobials, bulk trade — The Hindu, 20 Nov 2026AMR as a public-health concern; NDCT 'New Drug' amendment; separate bulk-drug sale licence; draft status
- 2National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017–2021 — WHO India2017---2021) — first national AMR plan and its multi-sector framework
- 3Lapses in the process of drug approval in India — PRS Legislative Research59th Standing Committee Report (2012) on CDSCO approval lapses
- 4Standing Committee Report on the Drugs and Cosmetics (Amendment) Bill, 2013 — PRS Legislative Researchweak State and central drug-control infrastructure; recommendation to centralise manufacturing licences
- 5New global guidance aims to curb antibiotic pollution from manufacturing — WHO, 2024manufacturing pollution largely unregulated; discharge targets for regulators